This Genetic-Testing Stock Popped, Then Slipped, On Its FDA ApprovalInvestors Business Daily • 12/30/19
Myriad Genetics's stock surges after FDA approval of diagnostic test for pancreatic cancerMarket Watch • 12/30/19
Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Lynparza® (olaparib) In Patients with Germline BRCA-mutated Metastatic Pancreatic CancerGlobeNewsWire • 12/30/19
Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer GenesGlobeNewsWire • 12/14/19
Myriad (MYGN) Up 18.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/04/19
Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal ScreeningGlobeNewsWire • 12/04/19
Myriad Genetics Announces Regulatory Approval of the BRACAnalysis® Diagnostic System in Japan for Breast Cancer PatientsGlobeNewsWire • 11/21/19
The American College of Rheumatology Adds the Vectra® Test to List of Recommended Disease Activity Measures for Rheumatoid ArthritisGlobeNewsWire • 11/20/19
Myriad’s Prequel™ Prenatal Screen Demonstrates High Performance Across All Fetal-Fraction Levels in Women Undergoing Noninvasive Prenatal ScreeningGlobeNewsWire • 11/11/19
GeneSight® Psychotropic Test Improved Clinical Outcomes for People with Depression Who Were Taking Medications with Gene-Drug InteractionsGlobeNewsWire • 11/06/19
This Genetic-Testing Stock Plummeted 39% On A Massive Earnings MissInvestors Business Daily • 11/05/19
Myriad Genetics stock plunges to lead premarket losers after earnings miss by wide marginMarket Watch • 11/05/19